VolitionRx Limited entered into a securities purchase agreement on June 7, 2026, to offer and sell 2,960,000 shares of common stock and 1,480,000 warrants to purchasers at a combined offering price of $1.55 per share and warrant. The offering, closed on June 9, 2026, is expected to yield approximately $4.1 million in net proceeds to be used for research, product development, clinical studies, working capital, and debt repayment. VolitionRx Limited is a biotechnology company focused on developing and commercializing products and diagnostic tools.
